Impact BioMedical (IBO) vs SCYNEXIS (SCYX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
SCYNEXIS (SCYX) has outperformed Impact BioMedical (IBO) over the past year, losing 24.7% versus a loss of 42.7%. SCYNEXIS is the larger company by market cap ($42.0 million vs $35.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IBO | SCYX |
|---|---|---|
| Share price | $4.11 | $4.22 |
| Market cap | $35.11M | $41.99M |
| 1-day change | -8.26% | -11.72% |
| YTD return | -29.92% | -5.46% |
| 1-year return | -42.73% | -24.65% |
| 5-year return | — | -89.27% |
| P/E ratio (TTM) | 0.37 | — |
| EPS (TTM) | $11.11 | $-0.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.51 | $9.12 |
| 52-week low | $4.10 | $3.53 |
| Distance from 52-week high | -60.88% | -53.73% |
| Average volume | 11.61K | 274.80K |
| Shares outstanding | 8.54M | 9.95M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SCYX has outperformed IBO by 18.1 percentage points over the past year.
IBO vs SCYX FAQ
Which is bigger, Impact BioMedical or SCYNEXIS?
SCYNEXIS (SCYX) is larger, with a market capitalization of $41.99M compared with $35.11M for Impact BioMedical (IBO).
Which stock has performed better over the past year, IBO or SCYX?
SCYX returned -24.65% over the past 12 months, compared with -42.73% for IBO (price return, excluding dividends). Past performance does not predict future results.
Are Impact BioMedical and SCYNEXIS in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.